Priveterra Acquisition Corp.
Status: Deal Closed
U=S+W/3
W=S@11.5
IPO Proceeds, $M | $276.00M |
---|---|
IPO Date | Feb 9, 2021 |
CEO | Robert Palmisano |
Left Lead | Wells Fargo |
IPO Cash in Trust | 100.0% |
SPAC Tenor | 24 + 6 |
IPO Sector |
Healthcare
Medical technology |
IPO Geography | Global |
Target Company | AEON Biopharma |
Deal Announced | Dec 13, 2022 |
Deal Size, $M | $220.80M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | Jul 3, 2023 |
Amendment Vote | Feb 10, 2023 |
Closing Date | Jul 21, 2023 |
Formerly PMGM
AEON
AEON/W
Price | $0.87 |
---|---|
Last closing price | $0.90 |
H/L, today | $0.62 / $0.90 |
H/L, 52-week | $3.37 / $11.88 |
Volume, today | 2,961 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Priveterra Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 44 filings and events
- 3 underwriters
- 3 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Robert Palmisano | 76 | Chairman and Chief Executive Officer |
Vikram Malik | 58 | President and Director |
Oleg Grodnensky | 43 | Chief Operating Officer and Chief Financial Officer |
David Meredith | 52 | Chief Legal Officer and Secretary |
Lance A. Berry | 48 | Director |
James A. Lightman | 62 | Director |
Julie B. Andrews | 49 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Wells Fargo | Joint BR | 11,520,000 | units |
Guggenheim Securities | Joint BR | 9,360,000 | |
Odeon Capital Group | 3,120,000 | ||
24,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.